← Leaderboards
Gangning Liang
University Of Southern California
$3,653,423
Attributed
$4,557,844
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $735.7K · FY2008–25$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,557,844 · 7
By mechanism
R01$2,927,931 · 3
R21$1,629,913 · 4
Top collaborators
- Hooman Djaladat2 shared
- Inderbir Gill2 shared
- Peter A Jones2 shared
- Siamak Daneshmand1 shared
Most similar at University Of Southern California
Same institution · by research overlap
- Inderbir Gill$1,251,091
- Hooman Djaladat$213,327
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsStagingCancer PatientUnited StatesMalignant Neoplasm Of Urinary BladderRecurrenceDna MethylationDiagnosisOperative Surgical ProceduresCancer DiagnosisEpigenetic ProcessCessation Of LifeBladder NeoplasmTumorigenesisCell LineUrineNormal Tissue MorphologyDiagnosticExcisionBladderMolecularOncogenesCancer Cell
Grant awards (18)
DNA Methylation Markers for early detection and monitoring the trajectory of tumor burden in Bladder Cancer$426,828
R21 · FY2025 · CA · contact PI
Using DNA Methylation Markers for Diagnosis and Prognosis of Upper Tract Urothelial Carcinoma$194,013
R21 · FY2025 · CA · contact PI
Using DNA Methylation Markers for Diagnosis and Prognosis of Upper Tract Urothelial Carcinoma$232,640
R21 · FY2024 · CA · contact PI
Using DNA methylation markers to improve the predictive accuracy and utility of needle biopsiesfor determining prostate cancer aggressiveness$179,438
R21 · FY2017 · CA · contact PI
Using DNA methylation markers to improve the predictive accuracy and utility of needle biopsiesfor determining prostate cancer aggressiveness$215,325
R21 · FY2016 · CA · contact PI
De Novo DNA Methylation in Bladder Cancer$284,702
R01 · FY2014 · CA · contact PI
De Novo DNA Methylation in Bladder Cancer$275,896
R01 · FY2013 · CA · contact PI
Determining the mechanistic and therapeutic roles of microRNAs in bladder cancer$245,201
R01 · FY2013 · CA · contact PI
Identification of a sensitive and specific panel of DNA methylated markers to imp$167,649
R21 · FY2013 · CA · contact PI
Epigentic Alterations in Pre-malignant Tissue of the Bladder$260,852
R01 · FY2012 · CA · contact PI
Determining the mechanistic and therapeutic roles of microRNAs in bladder cancer$260,852
R01 · FY2012 · CA · contact PI
Identification of a sensitive and specific panel of DNA methylated markers to imp$214,020
R21 · FY2012 · CA · contact PI
Determining the mechanistic and therapeutic roles of microRNAs in bladder cancer$260,852
R01 · FY2011 · CA · contact PI
Epigentic Alterations in Pre-malignant Tissue of the Bladder$260,852
R01 · FY2011 · CA · contact PI
Epigentic Alterations in Pre-malignant Tissue of the Bladder$268,920
R01 · FY2010 · CA · contact PI
Determining the mechanistic and therapeutic roles of microRNAs in bladder cancer$268,920
R01 · FY2010 · CA · contact PI
Epigentic Alterations in Pre-malignant Tissue of the Bladder$270,304
R01 · FY2009 · CA · contact PI
Epigentic Alterations in Pre-malignant Tissue of the Bladder$270,580
R01 · FY2008 · CA · contact PI